@2024 Afarand., IRAN
ISSN: 2252-0805 The Horizon of Medical Sciences 2013;19(2):67-70
ISSN: 2252-0805 The Horizon of Medical Sciences 2013;19(2):67-70
Effect of Short-time Consumption of Oral Magnesium Sulfate on Blood Glucose and Serum Lipids in Streptozotocin-induced Diabetic Male Rats
ARTICLE INFO
Article Type
Original ResearchAuthors
Shahraki M. R. (*)Mirshekari H. (1)
Khamar Moghadam S. (2)
(*) Department of Physiology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
(1) Amiralmomenin Clinic, Zahedan Health Center, Zahedan University of Medical Sciences, Zahedan, Iran
(2) EmergencyDepartment, Khatam Hospital, Zahedan University of Medical Sciences, Zabol, Iran
Correspondence
Address: Department of Physiology, Faculty of Medicine, Zahedan University of Medical Sciences Paradise, Khalij-e-Fars Boulevard, Zahedan, Iran. Postal Code: 43175- 98168Phone: +985413414550
Fax: +985413414563
m_shahrakim@zaums.ac.ir
Article History
Received: January 8, 2013Accepted: June 18, 2013
ePublished: June 25, 2013
BRIEF TEXT
CITIATION LINKS
[1] Islam MS, Loots du T. Diabetes, metallothionein and zinc interactions: A review. Biofactors. 2007;29(4):203-12.
[2] Otoom SA, Al-Safi SA, Kerem ZK, Alkofahi A. The use of medicinal herbs by diabetic Jordanian patients. J Herb Pharmacother. 2006;6(2):31-41.
[3] Herdzik E, Safranow K, Ciechanowski K, Byra E, Goldyn U. Comparison of ADA and WHO diagnostic criteria for diabetes diagnosis and other categories of glucose intolerance. Pol Merkur Lekarski. 2002;13(76):316- 20.
[4] Valk HW. Magnesium in diabetes mellitus. Neth J Med. 1999;54(4):139-46.
[5] Singh DL, Bhattarai MD. High prevalence of diabetes and impaired fasting glycaemia in urban Nepal. Diabet Med. 2003;20(2):170-1.
[6] Sasaki H, Kawasaki T, Ogaki T, Kobayashi S, Itoh K, Yoshimizu Y, et al. The prevalence of diabetes mellitus and impaired fasting glucose/glycaemia (IFG) in suburban and rural Nepal-the communities-based cross-sectional study during the democratic movements in 1990. Diabet Res Clin Pract. 2005;67(2):167-74.
[7] Tseng CH, Chong CK, Sheu JJ, Wu TH, Tseng CP. Prevalence and risk factors for stroke in Type 2 diabetic patients in Taiwan: A cross-sectional survey of a national sample by telephone interview. Diabet Med. 2005;22(4):477-82.
[8] Kuvandik G, Cetin M, Genctoy G, Horoz M, Duru M, Akcali C, et al. The prevalance, epidemiology and risk factors for onychomycosis in hemodialysis patients. BMC Infect Dis. 2007;7:102.
[9] Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-64.
[10] Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med. 1986;314(8):488-500.
[11] Gupta R, Sharma KK, Gupta A, Agrawal A, Mohan I, Gupta VP, et al. Persistent high prevalence of cardiovascular risk factors in the urban middle class in India: Jaipur heart watch-5. J Assoc Physicians India. 2012;60:11-6.
[12] Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. J Nutr. 2003;133(9):2879-82.
[13] Keshavarz M, Soltani N, Mansoori M, Hasanein P. Oral magnesium sulfate in prevention of diabetic neuropathy in mic. Tehran Univ Med Sci J. 2006;64(6):37-45. [Persian]
[14] Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: A review. Diabet Med. 2003;20(2):88-98.
[15] Elamin A, Tuvemo T. Magnesium and insulindependent diabetes mellitus. Diabetes Res Clin Pract. 1990;10(3):203-9.
[16] Fugono J, Fujimoto K, Yasui H, Kawabe K, Yoshikawa Y, Kojima Y, et al. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc (II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration. Drug Metab Pharmacokinet. 2002;17(4):340-7.
[17] Baydas B, Karagoz S, Meral I. Effects of oral zinc and magnesium supplementation on serum thyroid hormone and lipid levels in experimentally induced diabetic rats. Biol Trace Elem Res. 2002;88(3):247-53.
[18] Corica F, Allegra A, Di Benedetto A, Giacobbe MS, Romano G, Cucinotta D, et al. Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus. Magnes Res. 1994;7(1):43-7.
[19] Olatunji LA, Soladoye AO. Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid peroxidation in fructose-fed rats. Pathophysiology. 2007;14(1):11-5.
[20] Balon TW, Gu JL, Tokuyama Y, Jasman AP, Nadler JL. Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Am J Physiol. 1995;269(4):745-52.
[21] Soltani N, Keshavarz M, Sohanaki H, Dehpour AR, Zahedi Asl S. Oral magnesium administration prevents vascular complications in STZ-diabetic rats. Life Sci. 2005;76(13):1455-64.
[22] Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Mansoori M, Soltani N. Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats. Diabetes Res Clin Pract. 2006;73(1):17-22.
[23] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
[2] Otoom SA, Al-Safi SA, Kerem ZK, Alkofahi A. The use of medicinal herbs by diabetic Jordanian patients. J Herb Pharmacother. 2006;6(2):31-41.
[3] Herdzik E, Safranow K, Ciechanowski K, Byra E, Goldyn U. Comparison of ADA and WHO diagnostic criteria for diabetes diagnosis and other categories of glucose intolerance. Pol Merkur Lekarski. 2002;13(76):316- 20.
[4] Valk HW. Magnesium in diabetes mellitus. Neth J Med. 1999;54(4):139-46.
[5] Singh DL, Bhattarai MD. High prevalence of diabetes and impaired fasting glycaemia in urban Nepal. Diabet Med. 2003;20(2):170-1.
[6] Sasaki H, Kawasaki T, Ogaki T, Kobayashi S, Itoh K, Yoshimizu Y, et al. The prevalence of diabetes mellitus and impaired fasting glucose/glycaemia (IFG) in suburban and rural Nepal-the communities-based cross-sectional study during the democratic movements in 1990. Diabet Res Clin Pract. 2005;67(2):167-74.
[7] Tseng CH, Chong CK, Sheu JJ, Wu TH, Tseng CP. Prevalence and risk factors for stroke in Type 2 diabetic patients in Taiwan: A cross-sectional survey of a national sample by telephone interview. Diabet Med. 2005;22(4):477-82.
[8] Kuvandik G, Cetin M, Genctoy G, Horoz M, Duru M, Akcali C, et al. The prevalance, epidemiology and risk factors for onychomycosis in hemodialysis patients. BMC Infect Dis. 2007;7:102.
[9] Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-64.
[10] Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med. 1986;314(8):488-500.
[11] Gupta R, Sharma KK, Gupta A, Agrawal A, Mohan I, Gupta VP, et al. Persistent high prevalence of cardiovascular risk factors in the urban middle class in India: Jaipur heart watch-5. J Assoc Physicians India. 2012;60:11-6.
[12] Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of US adults. J Nutr. 2003;133(9):2879-82.
[13] Keshavarz M, Soltani N, Mansoori M, Hasanein P. Oral magnesium sulfate in prevention of diabetic neuropathy in mic. Tehran Univ Med Sci J. 2006;64(6):37-45. [Persian]
[14] Spruce MC, Potter J, Coppini DV. The pathogenesis and management of painful diabetic neuropathy: A review. Diabet Med. 2003;20(2):88-98.
[15] Elamin A, Tuvemo T. Magnesium and insulindependent diabetes mellitus. Diabetes Res Clin Pract. 1990;10(3):203-9.
[16] Fugono J, Fujimoto K, Yasui H, Kawabe K, Yoshikawa Y, Kojima Y, et al. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc (II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration. Drug Metab Pharmacokinet. 2002;17(4):340-7.
[17] Baydas B, Karagoz S, Meral I. Effects of oral zinc and magnesium supplementation on serum thyroid hormone and lipid levels in experimentally induced diabetic rats. Biol Trace Elem Res. 2002;88(3):247-53.
[18] Corica F, Allegra A, Di Benedetto A, Giacobbe MS, Romano G, Cucinotta D, et al. Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus. Magnes Res. 1994;7(1):43-7.
[19] Olatunji LA, Soladoye AO. Increased magnesium intake prevents hyperlipidemia and insulin resistance and reduces lipid peroxidation in fructose-fed rats. Pathophysiology. 2007;14(1):11-5.
[20] Balon TW, Gu JL, Tokuyama Y, Jasman AP, Nadler JL. Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Am J Physiol. 1995;269(4):745-52.
[21] Soltani N, Keshavarz M, Sohanaki H, Dehpour AR, Zahedi Asl S. Oral magnesium administration prevents vascular complications in STZ-diabetic rats. Life Sci. 2005;76(13):1455-64.
[22] Hasanein P, Parviz M, Keshavarz M, Javanmardi K, Mansoori M, Soltani N. Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats. Diabetes Res Clin Pract. 2006;73(1):17-22.
[23] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.